A Study of MK-1084 With Midazolam and Digoxin in Healthy Participants (MK-1084-009)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 3, 2024

Primary Completion Date

October 28, 2024

Study Completion Date

October 28, 2024

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

MK-1084

Oral administration

DRUG

Midazolam

Oral administration

DRUG

Digoxin

Oral administration

Trial Locations (1)

Celerion ( Site 0001), Tempe

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT06575933 - A Study of MK-1084 With Midazolam and Digoxin in Healthy Participants (MK-1084-009) | Biotech Hunter | Biotech Hunter